These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 33675543)

  • 1. Clinical value of 2D speckle tracking imaging in evaluating the effect of percutaneous intramyocardial septal radiofrequency ablation in patients with hypertrophic obstructive cardiomyopathy.
    Qian D; Zhou X; Liu H; Cao L
    J Clin Ultrasound; 2021 Jul; 49(6):554-562. PubMed ID: 33675543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy and safety of transthoracic echocardiography-guided percutaneous intramyocardial septal radiofrequency ablation for the treatment of patients with obstructive hypertrophic cardiomyopathy].
    Liu LW; Zuo L; Zhou MY; Li J; Zhou XD; He GB; Zhang J; Zhang JZ; Liu B; Yang J; Xu B
    Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Apr; 47(4):284-290. PubMed ID: 31060187
    [No Abstract]   [Full Text] [Related]  

  • 3. Myocardial perfusion improvement and mechanism after percutaneous intramyocardial septal radiofrequency ablation in obstructive hypertrophic cardiomyopathy: a study of myocardial contrast echocardiography.
    Yao L; Ta S; Wang J; Han C; Lei C; Li W; Li J; Wang B; Zhao X; Liu L
    Int J Cardiovasc Imaging; 2024 Jul; 40(7):1483-1492. PubMed ID: 38709352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of left ventricular mass, left atrial size, and N-terminal pro-B-type natriuretic peptide level following alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy.
    Dąbrowski M; Kukuła K; Kłopotowski M; Bekta P; Śpiewak M; Mazurkiewicz Ł; Tyczyński P; Orczykowski M; Parma R; Witkowski A
    Kardiol Pol; 2019; 77(2):181-189. PubMed ID: 30566209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Obstructive Cardiomyopathy.
    Liu L; Li J; Zuo L; Zhang J; Zhou M; Xu B; Hahn RT; Leon MB; Hsi DH; Ge J; Zhou X; Zhang J; Ge S; Xiong L
    J Am Coll Cardiol; 2018 Oct; 72(16):1898-1909. PubMed ID: 30309466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Left ventricular longitudinal systolic function after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a long-term follow-up study focused on speckle tracking echocardiography.
    Sommer A; Poulsen SH; Mogensen J; Thuesen L; Egeblad H
    Eur J Echocardiogr; 2010 Dec; 11(10):883-8. PubMed ID: 20667848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myocardial mechanics of percutaneous intramyocardial septal radiofrequency ablation.
    Li J; Zhang J; Shi Y; Sievert H; Taub CC; Bertog S; Ta S; Changhui L; Senser E; Wang J; Hu R; Huang J; Ruan F; Han Y; Li X; Wang B; Zhao X; Liu J; Hsi DH; Liu L
    Heart; 2023 Jan; 109(4):289-296. PubMed ID: 36270787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Midterm Outcomes of Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Cardiomyopathy: A Single-Center, Observational Study.
    Xie X; Chen S; Cui Y; Zhou Z; Lu J; Du Z; Ding J; Xing K; Zhang Y; Zhou Y; Li J; Guo X
    J Am Heart Assoc; 2024 Aug; 13(15):e034080. PubMed ID: 39056345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short time effects of two radiofrequency ablation methods on hypertrophic obstructive cardiomyopathy.
    He YG; Dong Y; Yang SH; Yang F; Yin JL; Zhao HQ; Zhao YJ
    Clin Cardiol; 2024 Feb; 47(3):e24217. PubMed ID: 38439605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Percutaneous Intramyocardial Septal Radiofrequency Ablation in Patients With Drug-Refractory Hypertrophic Obstructive Cardiomyopathy.
    Zhou M; Ta S; Hahn RT; Hsi DH; Leon MB; Hu R; Zhang J; Zuo L; Li J; Wang J; Wang B; Zhu X; Liu J; Han Y; Li X; Xu B; Zhang L; Hou L; Han C; Liu J; Liu L
    JAMA Cardiol; 2022 May; 7(5):529-538. PubMed ID: 35353129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amount of left ventricular hypertrophy determines the plasma N-terminal pro-brain natriuretic peptide level in patients with hypertrophic cardiomyopathy and normal left ventricular ejection fraction.
    Kim SW; Park SW; Lim SH; Kwon SU; Choi YJ; Park MK; Lee SC; Lee SH; Park JE; Jeon ES
    Clin Cardiol; 2006 Apr; 29(4):155-60. PubMed ID: 16649724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percutaneous intramyocardial septal radiofrequency ablation after 5-year follow-up.
    Ta S; Li J; Hsi DH; Hu R; Lei C; Shan B; Li W; Wang J; Wang B; Kang N; Li X; Liu J; Qi C; Huang J; Han Y; Ruan F; Zhang J; Liu L
    Heart; 2024 May; 110(11):792-799. PubMed ID: 38388470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peak systolic longitudinal strain of the lateral left ventricular wall improves after septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: a follow-up study using speckle tracking echocardiography.
    Faber L; Prinz C; Welge D; Hering D; Butz T; Oldenburg O; Bogunovic N; Horstkotte D
    Int J Cardiovasc Imaging; 2011 Mar; 27(3):325-33. PubMed ID: 20694748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Septal reduction therapy using nonalcohol agent in hypertrophic obstructive cardiomyopathy: Single center experience.
    Asil S; Kaya B; Canpolat U; Yorgun H; Şahiner L; Çöteli C; Arat A; Aytemir K
    Catheter Cardiovasc Interv; 2018 Sep; 92(3):557-565. PubMed ID: 29205803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dyssynchronization reduces dynamic obstruction without affecting systolic function in patients with hypertrophic obstructive cardiomyopathy: a pilot study.
    Giraldeau G; Duchateau N; Bijnens B; Gabrielli L; Penela D; Evertz R; Mont L; Brugada J; Berruezo A; Sitges M
    Int J Cardiovasc Imaging; 2016 Aug; 32(8):1179-88. PubMed ID: 27146905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma N-terminal pro-brain natriuretic peptide: a marker of left ventricular hypertrophy in hypertrophic cardiomyopathy.
    Brito D; Matias JS; Sargento L; Cabral MJ; Madeira HC
    Rev Port Cardiol; 2004 Dec; 23(12):1557-82. PubMed ID: 15732658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Percutaneous trans-apex intra-septal radiofrequency ablation of hypertrophic cardiomyopathy.
    Zuo L; Sun C; Yang J; Liu B; Zhou M; Guo R; Yu S; Ge J; Xiong L; Liu L
    Minim Invasive Ther Allied Technol; 2018 Apr; 27(2):97-100. PubMed ID: 28949276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum cardiac troponin I is related to increased left ventricular wall thickness, left ventricular dysfunction, and male gender in hypertrophic cardiomyopathy.
    Kubo T; Kitaoka H; Okawa M; Yamanaka S; Hirota T; Hoshikawa E; Hayato K; Yamasaki N; Matsumura Y; Yasuda N; Sugiura T; Doi YL
    Clin Cardiol; 2010 Feb; 33(2):E1-7. PubMed ID: 20043329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early remodelling of left ventricle and improvement of myocardial performance in patients after percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy.
    Veselka J; Honek T
    Int J Cardiol; 2003 Mar; 88(1):27-32. PubMed ID: 12659981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in left ventricular filling and left atrial function six months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy.
    Nagueh SF; Lakkis NM; Middleton KJ; Killip D; Zoghbi WA; Quiñones MA; Spencer WH
    J Am Coll Cardiol; 1999 Oct; 34(4):1123-8. PubMed ID: 10520801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.